
Glioblastoma breakthrough: 40-year-old dad is brain cancer-free after groundbreaking immunotherapy trial
How?
Read on to know more.
What happened?
In October 2022, 40-year-old Ben Trotman was diagnosed with terminal glioblastoma, the most common and deadliest form of brain cancer that typically carries a grim prognosis with a median survival of just 12–18 months. Yet, over two years after receiving a single dose of ipilimumab before standard care, Trotman reportedly remains cancer-free and healthy as ever.
Under the care of consultant oncologist Dr. Paul Mulholland at UCLH (University College London Hospital), Trotman became part of an NHS-funded trial that administers ipilimumab, a checkpoint inhibitor designed to boost the immune system, before traditional surgery, radiotherapy, and chemotherapy.
Two years later, his scans show no signs of recurrence, an unprecedented outcome in glioblastoma treatment.
The medical marvel
The new clinical trial for the most deadly type of brain cancer, glioblastoma, which helped Ben with another shot at life, is looking for patients to join after an incredible success story. Organized by the NHS, this study aims to enroll 16 people over 18 months and is dedicated to Baroness Margaret McDonagh, who lost her battle with the disease.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Villas For Sale in Dubai Might Surprise You
Dubai villas | search ads
Get Deals
Undo
Patients diagnosed with glioblastoma will receive an immunotherapy drug called ipilimumab before starting standard treatments, making the most of their immune systems when they are at their strongest.
The trial is being led by experts at University College London Hospital's National Hospital for Neurology and Neurosurgery. It follows a previous study with the same drug, which had to close because not enough patients joined.
The trial honors the late Baroness Margaret McDonagh's memory and, like Trotman, participants receive ipilimumab to prime their immune defenses, with hopes of replicating his reassuring response.
Ipilimumab: The key behind the breakthrough
Ipilimumab is a monoclonal antibody that blocks CTLA-4, an immune checkpoint. In cancers like melanoma, it enhances T-cell activity, enabling the body to attack tumors. When used before standard glioblastoma therapy, it primes the immune system to better target cancer cells.
In Trotman's case, it appears to have either eradicated or dramatically controlled his tumor, an outcome never before reported in this context.
This 'window-of-opportunity' pre-treatment approach is groundbreaking. By delivering immunotherapy before surgery, it maximizes immune activation and potentially aids post-operative cancer control, a novel strategy in glioblastoma care.
What is glioblastoma?
Glioblastoma, previously known as glioblastoma multiforme or GBM, is the most common and aggressive type of primary brain cancer in adults.
Glioblastoma originates from astrocytes, a type of glial cell that supports nerve cells in the brain and spinal cord. Glioblastoma is classified as a Grade IV tumor, meaning it's highly aggressive, grows rapidly, and infiltrates surrounding brain tissue. The exact cause of most glioblastomas is unknown. However, it is understood that the disease develops when brain cells undergo DNA mutations that cause them to grow and multiply uncontrollably.
The prognosis for glioblastoma is generally poor, with a median survival of about 12-18 months after diagnosis. The five-year survival rate is around 5%, meaning about 5% of patients are still alive five years after their diagnosis. Glioblastoma almost always recurs despite maximal treatment.
Hence, Trotman's cancer-free scans more than two years post-treatment represent a hopeful breakthrough. It suggests that bolstering immune readiness before conventional treatment might overcome glioblastoma's defenses.
The success story
The success story comes from Ben Trotman, who was diagnosed in October 2022 at the age of 40. Now, at 43, two years and eight months after his treatment, his scans are clear, and there are no traces of the tumor.
Dr. Paul Mulholland, the consultant medical oncologist who is leading this new trial and treated Ben, as reported by The Independent, shared, 'It is very unusual to have a clear scan with glioblastoma, especially when he didn't have the follow-up surgery that had been planned to remove all of the tumor that was initially visible on scans.
We hope that the immunotherapy and follow-up treatment Ben has had will hold his tumor at bay – and it has so far, which we are delighted to see.
'
Ben's life has changed significantly since his diagnosis; he got married to Emily just two months after receiving the immunotherapy treatment, and in April, they welcomed their daughter, Mabel. Emily expressed the emotional toll of Ben's diagnosis, saying, 'Getting this diagnosis was the most traumatic experience.
We were grappling with the fact that Ben had gone from being apparently perfectly healthy to having months to live.
Had we not met Dr. Mulholland, that would have been it for us. We felt we had a lucky break in an otherwise devastating situation.'
After the immunotherapy, Ben went on to have the standard treatments of radiotherapy and chemotherapy. He continues to have quarterly scans, which remain clear. Ben reflected on their journey, stating, 'We obviously don't know what the future holds, but having had the immunotherapy treatment and getting these encouraging scan results has given Emily and me a bit of hope.
We are focused on rebuilding the life we thought we had lost and enjoying being parents.
'
Dame Siobhain McDonagh MP led a successful fundraising campaign that gathered over £1 million to support this new trial. Her sister, Baroness McDonagh, sadly passed away from glioblastoma in 2023. Dame Siobhain shared, 'My beloved sister Margaret was appalled to discover that there had been no advances in brain cancer treatment for decades when she was diagnosed with glioblastoma.
Changing this was Margaret's final campaign and one that I have continued in her memory.
I am so grateful to the many people who knew and respected Margaret, who have come together and helped to raise funds and campaign for this new trial that we are calling Margaret's Trial.'
Dr. Mulholland is also thankful for Margaret and Siobhain's dedication, stating, 'When I met Margaret, she said to me, 'What can I do to support you to cure this disease?'.
I am incredibly grateful to her and to Siobhain, whose campaigning and fundraising in her sister's memory have led to this new clinical trial opening for patients with this most aggressive form of brain cancer that has such a poor prognosis, with most patients surviving just nine months after diagnosis.
The crucial element of this trial is that patients will have their immune system boosted by the drug before they have any other treatment, when they are fit and well enough to tolerate the immunotherapy.
We're taking everything we have learned from previous trials into this new study, and we are already planning follow-on trials. My aim is to find a cure for glioblastoma.'
What's ahead?
Led by Dr. Mulholland, the trial is expanding enrollment, aiming to confirm both safety and effectiveness. Currently, the National Brain Appeal is funding two positions to support Dr. Mulholland's vital research. The treatment will take place at the NIHR UCLH's Clinical Research Facility and the National Hospital for Neurology and Neurosurgery. Patients who are interested in participating in the new Win-Glio trial should discuss it with their consultant.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
an hour ago
- Time of India
Navi Mumbai hill quarry blasts endanger Tata cancer hospital
Navi Mumbai: The blasting activities at Kharghar Hill quarry have affected the Tata Cancer Hospital's functioning, besides causing distress to patients. The director of the Advanced Centre for Treatment, Research & Education in Cancer (ACTREC) has made an urgent appeal to the chief minister for intervention. The tehsildar has confirmed the quarry's lack of proper authorisation. The unlawful quarrying activities near Tata Cancer Hospital at Kharghar Hills, reportedly run by politicians and quarry operators, have resulted in damage to the hospital's buildings. These operations pose risks to patients and valuable medical equipment. The ACTREC director, Dr Pankaj Chaturvedi, in his letter to the CM stated, "It's the health of the patients that is more important and which is invisible and non-negotiable. The northwest hill near our cancer treatment facility has been severely impacted, with multiple pits excavated and green cover obliterated." You Can Also Check: Mumbai AQI | Weather in Mumbai | Bank Holidays in Mumbai | Public Holidays in Mumbai The continuous blasting and drilling operations produce excessive noise and dust pollution, jeopardising patient wellbeing and environmental health. Dr Chaturvedi has sought immediate governmental action to halt these "destructive" quarrying activities and explore sustainable alternatives. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like This Could Be the Best Time to Trade Gold in 5 Years IC Markets Learn More Undo He stressed the necessity of safeguarding cancer patients' health and welfare, protecting biodiversity, and maintaining eco-sensitive areas. An RTI query by Mumbai-based NGO NatConnect Foundation revealed that the quarry was operating without government approval. NatConnect director, B N Kumar, brought the matter to the chief minister's attention, who referred it to Raigad's district collector. Following a 2018 NGT ruling regarding Parsik Hill quarrying, environmental clearance is required for such operations. Dr Chaturvedi informed the CM about structural damage to 25-year-old hospital buildings, including cracked beams and slabs, weakening ACTREC campus structures. The deterioration has led to water infiltration during rains, causing fungal growth in cleanroom facilities and increasing patient risks. Dr Chaturvedi highlighted serious concerns about rising noise and dust pollution from uncontrolled quarrying adjacent to ACTREC. These ongoing activities have virtually destroyed a previously verdant hill. The dust affects residential sectors 22, 30, and 35, contaminating the hospital's sterile treatment areas. This creates considerable risks for vulnerable patients receiving crucial treatments like bone marrow transplants and proton therapy. Equipment requiring sterile environments faces persistent contamination risks. Dr Chaturvedi pointed out the quarrying operations' proximity to Pandavkada Waterfalls, an eco-tourism site, and the upcoming Kharghar-Turbhe tunnel. Jyoti Nadkarni from the Kharghar Hill and Wetlands forum noted regular observations of dump trucks transporting stones from the quarry area.


Time of India
an hour ago
- Time of India
Punjab increases monthly stipends for medical and dental college interns, residents
1 2 3 Chandigarh: Punjab finance minister Harpal Singh Cheema on Thursday announced an increase in the monthly stipends for interns, junior residents, and senior residents across govt medical and dental colleges in the state. The finance minister said there are currently 907 sanctioned intern posts, 1,408 for junior residents, and 754 for senior residents within Punjab's govt medical and dental colleges. The stipend for interns has been substantially raised from Rs 15,000 to Rs 22,000 per month. For junior residents, the new stipend structure will see a rise from the current Rs 67,968 per month to Rs 76,000 in the first year, Rs 77,000 in the second year, and Rs 78,000 in the third year. Similarly, senior residents will experience an increase from their current Rs 81,562 per month to Rs 92,000 in the first year, Rs 93,000 in the second year, and Rs 94,000 in the third year. Cheema reiterated the state govt's dedication to allocating ample resources for the education and health sectors. He said that the annual expenditure on these stipends, currently Rs 204.96 crore, will escalate to Rs 238.18 crore following this enhancement, representing an estimated annual increase of Rs 33.22 crore. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like You Won't Believe the Price of These Dubai Apartments Binghatti Developers FZE Get Offer Undo The finance minister affirmed the Punjab govt's resolve to enhance healthcare facilities throughout the state. He also mentioned the recent initiative to provide insurance coverage of Rs 10 lakh to every citizen, further emphasising the govt's focus on public welfare. Cheema assured that there will be no scarcity of funds for the continued development and improvement of healthcare infrastructure and services in Punjab. MSID:: 122881701 413 |


Time of India
2 hours ago
- Time of India
Federal heat on UnitedHealth sends shares tumbling — what you need to know
UnitedHealth Group Inc. (NYSE: UNH) saw its stock tumble nearly 4% today, continuing a steep downward spiral that has erased over 40% of its value in 2025 alone. The latest drop comes after the company confirmed that it's under both criminal and civil investigation by the U.S. Department of Justice (DOJ), related to its Medicare Advantage billing practices. How much has UnitedHealth stock lost in 2025? UnitedHealth stock has been among the worst performers on the S&P 500 this year. After starting 2025 near $525 per share, the stock has plummeted below $300, marking a more than 40% year-to-date drop. Key moments behind the plunge: by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like War Thunder - Register now for free and play against over 75 Million real Players War Thunder Play Now Undo April 2025 : Stock dropped 22% in a single day after missing Q1 earnings and slashing full-year guidance. May 2025 : CEO Andrew Witty resigned, adding leadership instability to the mix. July 2025 : Confirmation of DOJ investigation triggers renewed selling pressure. UnitedHealth Under DOJ Investigation: What's Going On? The Department of Justice (DOJ) is officially investigating UnitedHealth Group—America's largest health insurer—over its Medicare Advantage billing. The federal probes focus on whether the company artificially inflated patient risk scores to receive higher reimbursements from the government. Live Events UnitedHealth has confirmed receiving requests for information from the DOJ and stated it is cooperating fully with both criminal and civil investigations. While the company initially denied any criminal probe, it now admits it had proactively reached out to federal authorities earlier this year to clarify billing procedures and launch internal reviews. The DOJ's primary concern is centered on risk adjustment coding—a process that determines how much money the federal government pays insurers like UnitedHealth based on patients' medical conditions. Allegations suggest the company may have exaggerated diagnoses to collect excess payments from Medicare. How Did the Market React? As soon as news of the investigation surfaced, UnitedHealth stock took a hit . Shares fell over 4% in premarket trading , extending a broader decline that's seen the stock drop more than 40% year-to-date . This is not an isolated event. Earlier this year, UnitedHealth's stock experienced a major downturn when its former CEO unexpectedly resigned and the company withdrew its 2025 earnings guidance , citing cost overruns tied to its Medicare Advantage business. The current legal troubles are piling onto existing financial pressures, sending a clear message to investors: the road ahead may be rocky. The Core Issue: Medicare Advantage Risk Adjustment At the heart of the investigation is Medicare Advantage, a privately managed health insurance program funded by the federal government. Insurers like UnitedHealth receive payments based on the health risk profiles of their enrollees. The more serious the health conditions of a patient, the higher the risk score—and the larger the government payout. However, the DOJ is now investigating whether UnitedHealth manipulated these scores by inflating patient diagnoses. This isn't a new concern in the industry. Other insurers have faced similar audits and lawsuits. However, given UnitedHealth's size and influence, the implications could be significantly larger. Is it time to buy the dip on UnitedHealth stock? This is the big question facing investors. UNH stock may look cheap relative to historical valuation, but headline risk remains high . Here are two opposing scenarios: Bull Case: DOJ investigation ends with a manageable settlement. Medical cost inflation stabilizes. Leadership transition brings strategic clarity. Bear Case: Legal issues expand and trigger major fines or contract losses. Costs continue rising, forcing more earnings cuts. Institutional investors exit further, adding pressure. UnitedHealth's Response: Transparency, Audits & Reforms In response to the federal heat, UnitedHealth has taken several steps to present itself as compliant and transparent: Voluntary Disclosures : The company claims it initiated contact with the DOJ months ago and is cooperating with all requests. Third-party Audits : UnitedHealth says it is conducting external reviews of its risk adjustment processes, possibly signaling internal reforms are underway. Compliance Enhancements : The insurer is working on strengthening its internal controls to ensure billing accuracy going forward. Despite these efforts, legal experts suggest that even if no wrongdoing is found, the very existence of a federal investigation could lead to increased regulatory oversight, reputational damage, and mounting legal expenses. Other Headwinds Facing UnitedHealth The DOJ probe comes at a time when UnitedHealth is already navigating several internal and external challenges: 1. Leadership Shake-Up In May, longtime CEO Andrew Witty stepped down unexpectedly amid the growing storm. Former CEO Stephen Hemsley returned to stabilize the company and restore investor trust. 2. Rising Medical Costs Healthcare utilization surged in recent quarters, leading to higher-than-expected medical costs. UnitedHealth has warned of increased pressure on margins due to greater demand for surgeries, outpatient care, and chronic condition treatments. 3. Public Perception & Legal Risks Alongside regulatory attention, UnitedHealth is facing public scrutiny. If the DOJ finds grounds for prosecution, the company could face heavy fines, tighter compliance mandates, or even restrictions on future government contracts. Impact on Investors: What You Should Know For investors, the combination of legal risk, leadership uncertainty, and financial strain creates a complex risk profile. Key Concerns: Shareholder Value : With shares down over 40% YTD, portfolio exposure is already taking a hit. Earnings Outlook : With the company pulling its 2025 forecast, investors are left without clarity on future earnings potential. Regulatory Uncertainty : Prolonged investigations may drag down sentiment and stock performance even if no wrongdoing is proven. While some see the current dip as a buying opportunity in a fundamentally strong company, others warn that further volatility is likely in the coming quarters. What's Next: Timeline to Watch Upcoming Milestones: Earnings Report (Early August) : Investors are eagerly awaiting the next quarterly results. The focus will be on legal disclosures, medical cost trends, and updated guidance. DOJ Progress Updates : Any new details about the investigation's scope, possible subpoenas, or charges could further affect stock movement. Organizational Changes : Investors will also watch for more leadership reshuffles or board-level changes aimed at regaining market trust. Should You Be Worried? The UnitedHealth DOJ investigation is a serious matter—not just for the company, but for the broader health insurance industry. While the company has made moves toward transparency and reform, the federal probe introduces significant uncertainty around both earnings and regulatory compliance. If you're an investor, this is a moment to remain informed and cautious. Watching how the company navigates the legal, financial, and reputational fallout will be critical in determining whether UnitedHealth can regain its footing—or if deeper troubles lie ahead. FAQs: Q1: Why is UnitedHealth under DOJ investigation? The DOJ is probing UnitedHealth for possibly overbilling Medicare Advantage through inflated diagnoses. Q2: How did the DOJ probe affect UnitedHealth stock? UnitedHealth stock fell sharply after the DOJ launched its criminal and civil investigations.